Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 934 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan December 15, 2020 2022 ASCO Annual Meeting Research Round Up: New Research in Head... August 25, 2022 Registered Dietitian vs. Nutritionist March 3, 2021 The team of over 60 scientists investigating the age-old mystery of... September 24, 2020 Load more HOT NEWS 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research Keto Molecule Offers Clue for Preventing Colorectal Cancer 37-Year-Old Mom Breaks American Marathon Record
